Silybin: A Review of Its Targeted and Novel Agents for Treating Liver Diseases Based on Pathogenesis
- 23 September 2024
- journal article
- review article
- Published by Wiley in Phytotherapy Research
- Vol. 38 (12) , 5713-5740
Abstract
Liver disease represents a significant global public health concern. Silybin, derived from Silybum marianum, has been demonstrated to exhibit a range of beneficial properties, including anti‐inflammatory, antioxidative, antifibrotic, antiviral, and cytoprotective effects. These attributes render it a promising candidate for the treatment of liver fibrosis, cirrhosis, liver cancer, viral hepatitis, non‐alcoholic fatty liver disease, and other liver conditions. Nevertheless, its low solubility and low bioavailability have emerged as significant limitations in its clinical application. To address these limitations, researchers have developed a number of silybin formulations. This study presents a comprehensive review of the results of research on silybin for the treatment of liver diseases in recent decades, with a particular focus on novel formulations based on the pathogenesis of the disease. These include approaches targeting the liver via the CD44 receptor, folic acid, vitamin A, and others. Furthermore, the study presents the findings of studies that have employed nanotechnology to enhance the low bioavailability and low solubility of silybin. This includes the use of nanoparticles, liposomes, and nanosuspensions. This study reviews the application of silybin preparations in the treatment of global liver diseases. However, further high‐quality and more complete experimental studies are still required to gain a more comprehensive understanding of the efficacy and safety of these preparations. Finally, the study considers the issues that arise during the research of silybin formulations.Keywords
Funding Information
- Sichuan Provincial Administration of Traditional Chinese Medicine (No.2024MS042)
This publication has 153 references indexed in Scilit:
- Vicious Cycle‐Breaking Lipid Nanoparticles Remodeling Multicellular Crosstalk to Reverse Liver FibrosisAdvanced Materials, 2024
- Epidemiological Features of NAFLD From 1999 to 2018 in ChinaHepatology, 2020
- Folic acid conjugated polymeric drug delivery vehicle for targeted cancer detection in hepatocellular carcinomaJournal of Biomedical Materials Research Part A, 2019
- Roles of Albumin‐Binding Proteins in Cancer Progression and Biomimetic Targeted Drug DeliveryChemBioChem, 2018
- The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National LevelJAMA Oncology, 2017
- Enzymatic Synthesis of Homogeneous Chondroitin Sulfate OligosaccharidesAngewandte Chemie International Edition, 2017
- Liver fibrosis scores predict liver disease mortality in the United States populationHepatology, 2017
- Regulation of retinol‐binding protein 4 and retinol metabolism in fatty liver diseaseHepatology, 2016
- Deconvolution of the cellular origin in hepatocellular carcinoma: Hepatocytes take the center stageHepatology, 2016
- Treatment with silybin‐vitamin E‐phospholipid complex in patients with hepatitis C infectionJournal of Medical Virology, 2008